

For consumer (High Wycombe and Buckinghamshire) and trade media

News Release

Staff from Bucks-based company Takeda set to cycle 500km in four days to raise over £20,000 for Myeloma UK

Takeda UK Ltd, High Wycombe, Tuesday 23rd May 2017 - A team of 16 from local pharmaceutical company Takeda UK, including Managing Director Adam Zaeske, are getting 'back in the saddle' this weekend to take part in patient charity Myeloma UK's annual London to Paris cycle ride.

For the second year running, the Takeda team, known as the 'Myeloma Movers,' will cycle from Greenwich to Paris in just four days – and are on course to raise over £20,000 in the process.

The ride will start at the Royal Observatory in Greenwich on Thursday 25th May and from there cyclists will continue on towards Calais in France and beyond. The ride will conclude on Sunday 28th May when, under police escort, cyclists will ride up the cobbles to the Arc de Triomphe before crossing the finish line at the Eiffel Tower. The riders will each burn an astonishing 12,800 calories during the four-day ride - the equivalent of 64 glazed doughnuts!¹

Multiple myeloma, often described as a 'bone eating' cancer, is an incurable cancer of the plasma cells, which are a type of white blood cells found in the bone marrow and normally produce antibodies to help fight infection. It is the second most common type of blood cancer and there are around 5,000 new cases² and 2,700 deaths from multiple myeloma each year in the UK – that's around 7 people a day who die from this disease.² Myeloma UK is the only organisation in the UK dedicated exclusively to myeloma – aiming to improve standards of treatment and care through research, education and awareness raising.

Adam Zaeske, Managing Director Takeda UK & Ireland, commented: "I am extremely proud of the Takeda Myeloma Movers and all those taking part in the Myeloma UK London to Paris

ride. Myeloma UK leads the way in providing advocacy, funding for clinical trials and supporting patients and their families – and our contribution helps them achieve their goal of helping myeloma patients live with a better quality of life.”

If you would like to help the Takeda Myeloma Movers team reach their fundraising goal and in turn support the great work of Myeloma UK, you can donate at:

<https://www.justgiving.com/companyteams/MYELOMAMOVERS>

The 2017 Takeda Myeloma Movers team: Adam Zaeske, Andrew Telford, Cathy Wu, Justin Aleman, Daniel Armstrong, Inderdeep Chhokar, Jonathan Cowman, Jordan Gould, Katharina Geppert, Michelle Doyle, Eileen Phillips, Peter Rushton, Pradeep Kanuga, Shane Ryan, Simon Roffe, Will Whitaker.

-ends-

CONTACT FOR FURTHER INFORMATION:

Cressida Ward

Communications Director UK & Ireland

Takeda UK Ltd.

cressida.ward@takeda.com

+44(0)1628 537936

Claire Martin

Reynolds-Mackenzie Marlow

claire@reynoldsmackenzie.com

+44 (0)7900 886 579

About Takeda UK Ltd.

Takeda UK Ltd., located in High Wycombe, is the UK marketing and sales organisation of Takeda Pharmaceutical Company Limited, Osaka, Japan. Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. Additional information about Takeda UK Ltd. is available through its corporate website, www.takeda.co.uk.

References

1 Myeloma UK, London Paris Ride, 25-29 May 2017. Information Pack.

2 Cancer Research UK. Myeloma statistics. Available at: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma#heading-One>. Accessed May 2017